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Aims: Airway remodelling is a characteristic feature of asthma and is a dynamic process involving extracellular
matrix (ECM) production and its degradation. In this regard, the matrix metalloproteinases (MMPs) and their
specific inhibitors known as tissue inhibitors of metalloproteinases (TIMPs) have been shown to be important
in this process. In the present study, transforming growth factor (TGF)-β, MMP-2, MMP-9 and TIMP-1 levels
in serum samples of children with stable asthma and healthy controls were evaluated to determine whether
these levels show any difference between asthmatic and healthy children and whether or not these levels
change with atopic status.
Materials and Methods: Thirty-one mild to moderate stable asthmatic children aged 6-16 years (16 atopic,
15 non-atopic) who were followed in our clinic and 13 age-matched healthy volunteers were enrolled in the
study. Serum TGF-β, MMP-2, MMP-9 and TIMP-1 levels were measured by ELISA.
Results: There were no significant differences in serum levels of TGF-β, MMP-2 and TIMP-1 between patients
and controls. However, serum MMP-9 levels of asthmatic children were found to be significantly higher than
those of healthy controls. No difference was observed between atopic and non-atopic asthmatics for TGF-β,
MMP-2, MMP-9 and TIMP-1 levels.
Conclusions: Results of the present study support the evidence regarding the involvement of MMPs,
especially MMP-9, in the asthma pathogenesis. However, MMP-9 levels do not seem to be influenced by atopic
status, which is the most significant risk factor in childhood asthma.
Key Words: Asthma, children, metalloproteinase, airway remodelling

Astımlı Çocuklarda Serum Transforming Growth Factor-β (TGF-β),
Matrix Metalloproteinaz-2 (MMP-2), Matriks Metalloproteinaz-9 (MMP-9) ve
Metalloproteinaz Doku İnhibitörü-1 (TIMP-1) Düzeyleri
Amaç: Hava yollarında yeniden yapılanma (remodelling) ekstraselüler matriksin yapım ve yıkımını içeren
dinamik bir süreçtir ve astımın karakteristik özelliğidir. Matriks metalloproteinazları(MMP) ve
metalloproteinazların doku inhibitörleri olarak bilinen spesifik inhibitörleri (TIMP) bu süreçte önemli rol
oynarlar. Bu çalışmada stabil astımlı çocuklarda ve sağlıklı kontrollerde serum TGF-B,MMP-2, MMP-9 ve
TIMP-1 düzeylerini ölçerek bu belirteçlerin astımlı ve sağlıklı çocuklarda farklı olup olmadığının ve atopi
varlığından etkilenip etkilenmediğinin belirlenmesi amaçlandı.
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Yöntem ve Gereç: Polikliniğimizde tanı alan ve izlenen yaşları 6-16 arasında değişen 31 stabil astımlı olgu
(16 atopik, 15 nonatopik) ve benzer yaş grubundan 13 sağlıklı gönüllü çocuk çalışmaya alındı. Serum TGFβ,MMP-2, MMP-9 ve TIMP-1 düzeyleri ELISA yöntemi ile ölçüldü.
Bulgular: Hastalar ve kontroller arasında TGF-β,MMP-2, ve TIMP-1 düzeyleri açısından fark bulunmazken,
serum MMP-9 düzeyleri astımlı çocuklarda sağlıklı çocuklara göre belirgin yüksek bulundu. Atopik ve
nonatopik astımlılar arasında TGF-β, MMP-2, MMP-9 ve TIMP-1 düzeyleri açısından farklılık saptanmadı.
Sonuç: Bu çalışmanın sonuçları astım patogenezinde MMP’lerin özellikle MMP-9’un rol oynadığı yönünde
kanıtları desteklemektedir. MMP-9 düzeyleri çocukluk çağı astımında en önemli risk faktörlerinden olan
atopiden ise etkilememektedir.
Anahtar Sözcükler: Astım, çocuklar, metalloproteinaz, hava yolu yeniden yapılanması
* Funding of this study was provided by Ankara University Scientific Research Projects (project number:
200550809196).
This study was presented in EAACI 2007, Goteborg.
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Introduction
Asthma is the most common chronic illness in
childhood (1). Even if there are good guidelines for the
management of childhood asthma, knowledge related to
remodelling status and clinical severity is rather
inadequate (1-3).
Recent studies revealed that chronic inflammation and
airway remodelling are the two main factors in the
asthma pathogenesis (4,5). Epithelial destruction,
excessive production of profibrotic growth factors
(transforming growth factor-β [TGF-β]) and changes in
extracellular matrix (ECM) homeostasis were thought to
be responsible for airway remodelling (6). The matrix
metalloproteinases (MMPs) are probably the main
physiological mediators of ECM degradation (7). Tissue
matrix metalloproteinases inhibitor-1 (TIMP-1) is the
natural inhibitor of this process (7).
The aim of this study was to compare serum levels of
TGF-β, metalloproteinases (MMP-2, MMP-9) and their
inhibitor TIMP-1 in stable asthmatic patients and healthy
children and to evaluate whether these levels show any
difference between asthmatic and healthy children and
whether or not these levels change with atopic status.

Materials and Methods
Thirty-one mild to moderate stable asthmatic children
who were diagnosed as asthma according to the
international asthma diagnosis and treatment guidelines
and who were being followed in our clinic and also 13
age-matched healthy children were enrolled into the
study. Exclusion criterion for the patients was systemic
steroid usage during the last month. Stable asthma was
defined on the basis of lack of clinical symptoms such as
wheezing, tachypnea, and prolonged expiration time in
addition to peak expiratory flow rate greater than 80%
of predicted in patients who were able to undergo an
evaluation. Sixteen of the children with asthma were
atopic whereas 15 were non-atopic. Atopy was defined as
having at least one positive skin prick test or specific IgE
to common aeroallergens.
Venous blood samples of subjects were centrifuged at
3000 rpm for 5 minutes. Obtained serums were stored
at -20 °C until time of analysis. Serum TGF-β, MMP-2,
MMP-9 and TIMP-1 levels were determined by ELISA
(Quantikine, R&D systems, USA) method. The lowest
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limits of detection for the TGF-β, MMP-2, MMP-9 and
TIMP-1 assays were 15.4 pg/ml, 0.4 ng/ml, 0.156 ng/ml
and 0.08 ng/ml, respectively.
Demographic data was evaluated with Kruskal Wallis
variance analysis; serum levels of TGF-β,
metalloproteinases and TIMP-1 were compared with
Mann-Whitney U test. The ethics committee at our
institution approved the present study and written
informed consent was obtained from parents of all
participants.

Results
Some characteristics of the patients are given in Table
1. Serum TGF-β, MMP-2, MMP-9, and TIMP-1 levels are
compared in Figure. There were no statistical differences
in serum TGF-β and MMP-2 levels among the groups.
However, serum MMP-9 levels of asthmatic children
were significantly higher than those of healthy controls
(P=0.03).
Although serum TIMP-1 levels of asthmatic children
were higher than the control group, the difference
between them was not statistically significant. No
difference was observed between atopic and non-atopic
asthmatics for serum TGF-β, MMP-2, MMP-9 and TIMP1 levels, while MMP-9 levels were significantly higher
than those of the healthy controls both for atopic (P =
0.01) and non-atopic (P = 0.01) asthmatics (Table 2).
Table 1. Some characteristics of the groups.

Asthmatics
n=31

Controls
n=13

Median age (years)
(range)

8.9
(6-16)

9.5
(3-15)

Gender (Male/Female)

17/14

8/5

Asthma severity
Mild-persistent
Moderate-persistent

23
8

Inhaler steroid usage
Dosage (budesonide)
Duration (month)

25
200-400 mcg
1-30

Montelukast usage
Duration

8
3-12

-
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Figure. TGFb (pg/ml), MMP-2 (ng/ml), MMP-9 (ng/ml) and TIMP-1
(ng/ml).

No correlation was detected between the serum levels
of TGF-β, MMP-2, MMP-9 and TIMP-1 and the dosage or
duration of inhaler corticosteroid treatment.

Discussion
Deregulation of the proteolytic-antiproteolytic
network and inappropriate secretion of various MMPs by
stimulated structural or inflammatory cells are thought to
take part in the pathogenesis of numerous lung diseases
including asthma, chronic obstructive pulmonary disease
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(COPD), lung fibrosis, and lung cancer (8). The aim of
this study was to compare serum levels of TGF-β,
metalloproteinases (MMP-2, MMP-9) and their inhibitor
TIMP-1 in stable asthmatic patients and healthy children
and to evaluate their role in asthma. Although there are
some studies evaluating metalloproteinases in
bronchoalveolar fluid or sputum of asthmatic patients
(7,9), we could only find the study of Belleguic et al.
evaluating metalloproteinases in the blood of asthmatic
adults (10). They compared the levels of MMPs, eotaxin
and soluble interleukin-2 receptor in the plasma of
healthy subjects, atopic but non-asthmatic and asthmatic
patients. They found that the MMP-9 level was
significantly enhanced in acute severe asthma compared
with the others. No difference was found in TIMP-1 levels
in plasma. Furthermore, they speculated that the MMP9/TIMP-1 ratio in acute severe asthmatics may be higher
than in the other groups. Moreover, they did not observe
any difference in MMP-2 between the groups of patients
(10). Similarly, in the present study, serum MMP-9 levels
of stable asthmatic children were higher than those of
healthy controls and MMP-2 levels were not different
between the groups. These findings suggest that an
increase in the serum MMP-9 level may indicate a defect
in ECM homeostasis even in stable asthmatic children and
perhaps propose MMP-9 as a noninvasive marker of
inflammation and remodelling in asthma.

Table 2. Comparison of serum TGF-β, MMP-2, MMP-9 and TIMP-1 levels of atopic and non-atopic asthmatic patients.

Atopic asthmatics
n = 16

Non-atopic asthmatics
n = 15

Controls
n = 13

TGF-β (pg/ml)
mean ± SD
(Min-Max)

38.8 ± 13.8

39.7 ± 13.7

37.7 ± 15.6

4-52

8-59

4-58

MMP-2 (ng/ml)
mean ± SD
(Min-Max)

249.6 ± 52.6

266.1 ± 43.5

245.9 ± 37.0

130-220

160-350

170-290

P = 0.01
P = 0.01
MMP-9 (ng/ml)
mean ± SD
(Min-Max)

373.8 ± 239.5

378.7 ± 217.8

209.6 ± 103.2

72-1000

35-800

100-445

TIMP-1 (ng/ml)
mean ± SD
(Min-Max)

98.5 ± 30.5

100.6 ± 32.6

88.8 ± 11.4

62-183

40-180

71-111

TGF-β: tissue growth factor-β; MMP: matrix metalloproteinase; TIMP-1: tissue inhibitor of metalloproteinases.
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Structural changes in airways characterizing
remodelling may occur early in the natural history of
asthma, even before diagnosis can be made based on
clinical symptoms (1). A common limitation in evaluating
airway changes in childhood asthma is that invasive
maneuvers such as fiberoptic bronchoscopy with biopsy
studies are problematic for a variety of reasons including
ethical considerations. Although airway remodelling could
not be demonstrated by biopsy in the present study,
several recent studies in the literature provide important
supportive findings of our data. Pohunek et al. evaluated
markers of inflammation and tissue remodelling in
bronchial biopsies from children with early respiratory
symptoms before the clinical diagnosis of asthma. They
found that eosinophilic inflammation and airway
remodelling were present even before asthma diagnosis
based on clinical symptoms (1). In another study, Barbato
et al. analyzed bronchial studies of 23 asthmatic children
undergoing bronchoscopy for clinical indications other
than asthma. They reported that bronchial basement
membrane thickening was already present in children
with mild asthma (11). In their study, expression of TGFβ and its receptors was found to be similar in atopic and
non-atopic asthmatic children as well as children without
asthma. Likewise, in the present study, similar serum
TGF-β levels were detected in both asthmatic and healthy
children.
The relationship between airway remodelling, airway
inflammation and symptoms of asthma has been difficult
to elucidate. Both remodelling and loss of lung function in
asthma seem to occur in early childhood (12,13).
However, it is not known whether remodelling
contributes to loss of function or is even a marker for it.

Turk J Med Sci

In an interestingly designed study, Matsumoto et al.
measured sputum levels of MMP-9 and TIMP-1 and their
molar ratio in 26 asthmatic patients, and their
relationship with pulmonary function and airway wall
thickness was assessed by a computerized tomography
technique (5). They found that sputum MMP-9 levels and
MMP-9/TIMP-1 molar ratio were inversely correlated
with airway wall area. Matsumoto et al. interpreted these
findings as an absolute increase in TIMP-1 or its relative
excess over MMP-9 and decreased MMP-9/TIMP-1 molar
ratio in the asthmatic airway may be associated with
airway wall thickening (5). Doherty et al. also found the
ratio of MMP-9 to TIMP-1 reduced in bronchoalveolar
lavage fluid in asthmatic children (9). However, they also
did not evaluate serum levels of these factors. In this
respect, increased serum MMP-9 levels and slightly
increased TIMP-1 levels in the present study may indicate
homeostasis of a repair process according to these
findings.
Corticosteroids influence both inflammatory and
remodelling processes in asthma, although their effects
on ECM, MMPs and TIMPs are less clear. It has been
reported that moderate doses of inhaled corticosteroids
diminish MMP-9+ cells in the airways of patients with
asthma (14). In the present study, no associations were
detected between serum MMP-9 levels and duration or
dosage of inhaler corticosteroid treatment. Further
studies are needed to identify the effect of corticosteroids
on serum MMP levels.
In conclusion, the results of the present study support
the evidence about derangement of MMP/TIMP
homeostasis in the asthma pathogenesis regardless of the
atopic status.
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